Opinion

Video

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management

Author(s):

Balazs Halmos, MD,Julia Rotow, MD

Panelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.

  1. Dr Bestvina: What are the most pressing unanswered questions in ALK-positive and BRAF-positive management?
  2. How do you envision the treatment landscape evolving over the next 5 years?
Related Videos
Related Content